Plasma autoantibody biomarkers for diagnosis of lung cancer

Abstract

An immune-proteomic screening of AAb responses using protein arrays has identified two panels of Aab (antigen / antibody complexes) that can potentially differentiate lung adenocarcinoma from smoker controls as well as CT positive benign lung disease. The resulting biomarkers appear to have high specificity so that high risk subjects with a positive CT screen and a positive serum test should get more invasive test such as needle biopsy for a timely cancer diagnosis, among other advantages.

Description

[0001] Related Application Cross Reference [0002] This application claims priority to U.S. Provisional Application No. 62 / 277,786, filed January 12, 2016, which is incorporated herein by reference as if fully set forth herein. [0003] Statement on Federal Funding for Research and Development [0004] This invention was made with Government support under U01CA117374 awarded by the National Institutes of Health. The government has certain rights in this invention. technical field [0005] This article deals with biomarker complexes and assays in the field of lung cancer. Background technique [0006] The decline in lung cancer mortality is associated with CT screening, which has led to the increasing use of CT screening and improved detection of benign pulmonary nodules. Many of these individuals underwent unnecessarily expensive and invasive procedures. Therefore, a companion diagnostic is needed to stratify individuals with pulmonary nodules as high or low risk. [0...

AI Technical Summary

Problems solved by technology

CT scans are proven effective in reducing lung cancer mortality by 20%, but millions of CT-detected lung nodules remain undiagnosed as malignant or benign

Images